National Institute of Mental Health (NIMH)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Mental Health (NIMH) sits in the top decile of US sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count).

343 total trials 42 currently recruiting 256 completed early-phase tilt top decile by trial count

National Institute of Mental Health (NIMH): 343 sponsored US clinical trials, 42 recruiting.

National Institute of Mental Health (NIMH) sponsors 343 registered US clinical trials on ClinicalTrials.gov, 42 of them currently recruiting, and 256 completed. 29 of these trials are in Phase 3-4 (later-stage) and 106 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 21 trials.

Top-decile sponsor footprint

National Institute of Mental Health (NIMH) ranks in the top decile of sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

256 of 296 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

343 total, page 2 of 7

COMPLETED NA

Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients

NCT05092971

COMPLETED

Ask Suicide-Screening Questions (ASQ) for Youth With Autism Spectrum and Neurodevelopmental Disorders

NCT04317118

TERMINATED Phase 2

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT04821271

COMPLETED

Emotional, Social, Cognitive and Behavioral Sequalae of the COVID-19 Pandemic

NCT04823988

COMPLETED Phase 1

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005

COMPLETED

Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen

NCT04684615

COMPLETED

Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses

NCT04377100

COMPLETED

Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers

NCT04339790

TERMINATED Phase 1

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630

TERMINATED Phase 1

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT03912428

COMPLETED Phase 2

Estrogen Receptor Beta and Mood

NCT03689543

COMPLETED Phase 1

Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)

NCT03861000

COMPLETED NA

Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

NCT03289923

COMPLETED Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome

NCT02743377

TERMINATED

Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

NCT03507218

COMPLETED NA

Development of Non-Invasive Brain Stimulation Techniques

NCT03351764

COMPLETED

Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)

NCT03324646

TERMINATED

Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core

NCT03092687

COMPLETED NA

Effect of Transcranial Magnetic Stimulation to the Frontoparietal Attention Network on Anxiety Potentiated Startle

NCT03027414

TERMINATED Phase 1

Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)

NCT03030391

TERMINATED

Use of the Ask Suicide-Screening Questions (ASQ) in Pediatric Outpatient Settings

NCT02830334

COMPLETED NA

Main Study: Influence on Plasticity of Brain Temperature Sub-Study: Phase Triggered Paired Associative Stimulation (PAS)

NCT02363296

COMPLETED

Evaluation of a Novel PET Radioligand to Image OGA

NCT03632226

COMPLETED Phase 2

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

NCT02484456

COMPLETED

Spatial Context and Fear Learning

NCT02423044

COMPLETED

Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress

NCT02423031

COMPLETED

PET Imaging in Chronic Traumatic Encephalopathy

NCT02211820

COMPLETED Phase 1

Specific PET Radioligand Binding to Translocator Protein

NCT02181582

COMPLETED Phase 4

Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety

NCT02153944

COMPLETED

Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients

NCT02140177

COMPLETED Early Phase 1

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

NCT02147392

TERMINATED Phase 1

Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8

NCT02108015

COMPLETED

Imaging and Genetic Investigation of Learning and Decision Making

NCT01950377

TERMINATED

Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting

NCT02050867

TERMINATED Phase 1

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

NCT02049385

COMPLETED

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

NCT02230592

COMPLETED Phase 1

Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain

NCT01896843

TERMINATED Phase 2

A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism

NCT01887132

COMPLETED

Brain Inflammation in Major Depressive Disorder Background

NCT01851356

TERMINATED

Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

NCT01867398

COMPLETED

Study of [11C]DPA-713 for Temporal Lobe Epilepsy

NCT01793532

COMPLETED

A Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults

NCT01778478

TERMINATED

Near Infrared Spectroscopy in Children With Autism and ADHD

NCT01730079

TERMINATED Phase 1

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

NCT01712646

COMPLETED Phase 1

Translocator Protein and Inflammation After Traumatic Brain Injury

NCT01547780

TERMINATED

Mild Neurocognitive Disorder in HIV Infection of the Brain

NCT01547754

TERMINATED Phase 1

Imaging of Brain Receptors Using (11C)mGlu1

NCT01420952

TERMINATED Phase 1

Imaging of CB1 Receptors Using (11C)SD5024

NCT01399398

COMPLETED

(18F)FCWAY and the Blood-Brain Barrier

NCT01386476

COMPLETED

Study of Toddlers With Language Delay

NCT01339767

← Previous Page 2 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 61
Phase 2 45
Phase 3 8
Phase 4 21

What is open in the National Institute of Mental Health (NIMH) pipeline

42 recruiting of 343 indexed (12% open); 256 completed (75%).

Phase mix: 29 late (III/IV) vs 106 early (I/II) (early-phase heavy).

Top condition: Healthy (21 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Mental Health (NIMH): open-pipeline peers nationwide

Peers matched on 343 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 5%10%15%20%25% Total trials Recruiting share National Institute of Mental Health (NIMH)Children's Oncology GroupMontefiore Medical CenterOhio State University Comprehensive Cancer CenterCedars-Sinai Medical CenterAugusta UniversityUniversity of IowaDaiichi SankyoFriends Research Institute
National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 343 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this National Institute of Mental Health (NIMH) page

343 registered trials is a research-attention snapshot, not an endorsement of National Institute of Mental Health (NIMH) or any single study.

  • 42 of National Institute of Mental Health (NIMH)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institute of Mental Health (NIMH) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

National Institute of Mental Health (NIMH) pipeline card: 343 registered trials from official public datasets.Report a data error.